uptake of human -hexosaminidase by a specific glycoprotein recognition system on sinusoidal cell& Proc NatI Acad Sci USA 1979;76:2774-8. is protective against atherosclerotic heart disease (5), such that a decrease in HDL-C is a strong predictor of coronary heart disease (6). Therefore,measurement of the cholesterol content of all plasma lipoproteins-a cholesterol profile-is very useful for accurate assessment of risk for atherosclerosis Sequential ultracentrifugation can separate lipoproteins into classes according to density, so that their cholesterol content can then be accurately measured. However, this method is time consuming and not well suited to clinical applications. The most common clinical laboratory procedures for measuring cholesterol profiles involve multiple analyses of differentaliquot.s of the same plasma sample. PC is measured in one aliquot, apolipoprotein (ape) B-containing lipoproteins are precipitated from a second aliquot, and the cholesterol measured in the remaining supernate of the second aliquot is HDL-C. VLDL-C either is estimated by using the formula of Friedewald et al. (8) after the triglycerides are measured in a third aliquot or is measured directly after ultracentrifugal isolation of the VLDL 3Nonstandard abbreviations:
fraction (9). LDL-C is not measured directly, but is calculated by subtracting the HDL-C and VLDL-C values from the PC concentration; this reported LDL-C value therefore includes Lp(a)-C, L1)L-C, and IDL-C.
Multiple analyses make this procedure tedious and susceptible to analytical error.
Precipitation of lipoproteins with macromolecular polyanions (such as heparin and dextran sulfate) or with sodium phosphotungstate is commonly used to separate ape B-containing lipoproteins from the HDL fraction (10). Precipitationmethods, however, depend on complete and selective precipitation of the target lipoprotein. Incomplete precipitation of ape B-containing lipoproteins can lead to erroneous results.
The Vertical Auto Proffle (VAP) method was developed in our laboratory to proffle quantitatively the cholesterol in the major plasma lipoprotein fractions (11, 12) . The original VAP, designated here as yAP-I, involves short (35 miii, excluding deceleration time) density-gradient vertical ultracentrifugation, continuous enzymatic analysis of cholesterol content in the centrifuge tube by a Technicon AutoAnalyzer (Technicon Instruments, Tarrytown, NY), and computer-assisted digitization and decomposition of the absorbance curve to provide both PC results and the cholesterol values of the lipoprotein classes.VAP-I provides rapid analysis of lipoprotein profiles in a single plasma sample; however, the relatively large amount of sample (1.3 mL) required by yAP-I makes it unsuitable for analysis of small-volume (e.g., fingerstick) blood samples. In addition, the YAP-I instrumentation is cumbersome, making its operation and maintenance somewhat difficult.
To overcome these problems, we developed a new, highly sensitive analytical system, VAP-llfs (fingerstick), based on controlled dispersion of the sample during analysis. Tabletop ultracentrifugation reduces the sample volume needed and decreases analysis time. Here we describe the results obtained from the VAP-llfs method and its application to the determination of lipoprotein cholesterol distribution in fingerstick blood samples.
Materials and Methods

Single vertical-spin density-gradient ultracentrifuga-
tion. Separation of lipoproteins by single vertical-spin density-gradient ultracentrifugation was as previously described (11), except that the plasma samples were much smaller. Fresh plasma samples (18 &L) were diluted 30-fold with saline/EDTA solution (per liter: 9 g of NaCl, 1 mmol of EDTA, pH 7.4, density = 1.006 kg/L) and adjusted to a density of 1.21 kg/L by adding dry KBr. A discontinuous gradient was formed in 2-mL Polyallomer Quick Seal ultracentrifuge tubes (Beckman Instruments, Palo Alto, CA) by pipettung 1.35 mL of the salineIEDTA solution into a glass Pasteur pipette placed in each tube and then underlayering with 0.55 mL of density-adjusted plasma sample. Tubes were sealed, placed immediately in a Beckman TLV-100 rotor (which holds eight tubes), and centrifuged in a Beckman Controlled-dispersion flow analysis. The VAP-IIfs flow-analysis system, shown schematically in Figure 1 , consists of a tube-piercing needle assembly (Beckman Instruments), two peristaltic pumps to control flow rates of sample and reagent, a Plexiglas module with a Y-shaped capillary channel for mixing sample and reagent, a 1.5 m x 0.8 mm (i.d.) Teflon coil enclosed in a temperature-controlled glass chamber (37 #{176}C) that acts as the reactor, a spectrophotometric liquid-chromatographic detector (Pharmacia LKB, Uppsala, Sweden) with a micro-volume flow cell, a strip-chart recorder, and a computer to collect and analyze the absorbance data. The pump placed near the needle assembly controls the flow rate of cholesterol reagent; a pump placed downstream from the detector controls the flow rate of the reaction mixture containing the sample and reagent and can be used to adjust the sample-to-reagent ratio. Cholesterol reagent ("High performance"; Boehringer Mannheim Diagnostics, Indianapolis, IN) was prepared freshly each day in de-ionized, distilled water (250 g/L). Brij 35 (Sigma Chemicals Co., St. Louis, MO) was added to the reagent solution (25 mL'L) to facilitate the breakdown of lipoprotein particles. All liquid solutions, including the cholesterol reagent solution, were degassed under reduced pressure to minimize formation of air bubbles. After centrifugation, the sample tube was placed in the needle assembly, the top was removed, and the tube was carefully punctured at the bottom soas not to disturb the formed gradient. The sample was drawn into the Plexiglas module by the peristaltic pump downstream from the detector and was mixed continuously with a stream of cholesterol reagent. The flow rate of the reaction mixture was maintained at 1.1 mL/min (re-agent, 0.5 mLlmin; sample, 0.6 mL'min). The absorbance of the enzymatic cholesterol reaction product was monitored continuously at 505 nm as it passed through the detector. The system was washed briefly with water between samples by switching the flow from sample to water at the end of sample drain via the valve on the flow module; reagent flow was not interrupted at any time.
Computer-assisted analysis for lipoprotein classes.
Data were acquired and digitized with a Data Translation (Marlboro, MA) analog-to-digital conversion board and software developed in this laboratory. The digitized absorbance curve was then separated into its components ("decomposed")to quantify the cholesterol content in each lipoprotein class by use of other software previously developed in this laboratory. The algorithm, doscribed earlier (12), is based on the assumption that the curve shapes for the individual lipoprotein classesin a sample are the same as when isolated individual lipoprotein classes are analyzed with the YAP. The functional form of this curve was assumed to be bicameral gaussian with an exponential tail (12): an originally symmetrical gaussian peak in the centrifuged tube would be convoluted by flow and mixing factors to a form having a larger half-width on the trailing side than on the leading side and an exponential modification to the trailing side. Location in the profile and peak shape parameters (widths at half-height, peak height, and the exponent) for each lipoprotein class were determined by isolating individual lipoproteins by preparative ultracentrifugation and then analyzing the isolated lipoproteins in the VAP-IIfs procedure. After determining the peak times and peak shape parameters for each lipoprotein class, the area under each subcurve was determined. PC concentration was determined by adding the areas under all the subcurves; at each instant, the PC present is the sum of the contributions of the individual lipoprotein classes. A calibration plasma sample, for which the PC value was known accurately, was included in each rotor to calibrate the area in terms of cholesterol concentration. The PC of a sample can also be determined by comparing the total area under the undecomposed curve with that of the calibration plasma.
Cholesterol profiles. Venous and capillary blood samples (obtained via fingerstick) from 23 fasting subjects were collected simultaneously. Venous samples were collected into EDTA; fingerstick samples were collected into heparinized hematocrit tubes. Plasma was separated from the fingerstick blood samples by using a microhematocrit centrifuge. Venous samples were divided, and half were sent to the NWLRL for analysis as described below. Venous and fingerstick sample pairs were subjected to single vertical-spin density-gradient ultracentrifugation in the same rotor, according to the conditions described above, and cholesterol distribution was determined by the VAP-llfs method. All samples were analyzed within 5 days of collection.
Compartson of yAP-lift analysis with NWLRL method. Venous plllsmsl samples from the 23 subjectswere sent to the NWLRL for comparisonof analysis. Analyses in this Centers for Disease Control (CDC)-standardized laboratory were performed as follows:cholesterolwas assayed in whole plasma by an automated enzymatic system (Spectrum Multichromatic Analyzer; Abbott Labs., North Cliicage, IL 60064). The HDL fraction was obtained after chemical precipitation of VLDL and LDL with dextran sulfte-magnesium (Selected Method) (13); the choketerol in this fraction was quantified enzymatically by the Abbott Spectrum, with use of a separate calibration appropriate for low cholesterolvalues.
VLDL-C and LDL-C were quantified by using the Lipid Research Clinics Beta Quantification method (9), which involves ultracentrifugation of plasma to sopsrate VLDL (in the density <1.006 kg/L supernate) from LDL and HDL (in the density >1.006 kg/L infranate). The infranatant and supernatant fractions are assayed enzymatically for cholesterol content; LDL-C is determined as the difference between the infranatant cholesterol value and the HDL-C value determined previously. The VLDL-C reported is determined as the difference between the whole-plasma and the infranatant cholesterol values.
Assay performance of the Beta Quantification procedure was monitored by including normal and abovenormal quality-control sera (Q17, Q19; obtained from the CDC, Atlanta, GA) with each plasma assay run, including quality-control sera (aQ, from CDC; and DSC, from Solomon Park Research Labs., Kirkland, WA) in each precipitation run, and including a low-cholesterol quality-control serum (mQ; CDC) in each HDL-C assay run. In addition, performance in 'blind" assay of split duplicates was monitored monthly; the CVs for PC ranged between 1% and 3%; for HDL-C, between 0.5% and 2%; and for LDL-C, between 1.5% and 4%.
Statistical analysis. Total and lipoprotein cholesterol values are reported as mean ± SE. For comparisons between methods of analysis, we used two-tailed paired t-tests; differences were considered statistically significant atP <0.05. Mean paired differences are reported as mean ± SE. Correlations between the VAP-flfs and the NWLRL Beta Quantification methods were assessedby linear-regression analysis.
Results
Assay optimization.
In a preliminary study, we determined the effect of the flow rate of the reaction mixture The preliminary study involved undiluted plasma from a single pool. However, the high sensitivity of the flow-analysis system required that plasma be diluted for quantitative determination. To determine the degree of sample dilution required for quantification with optimum sensitivity, we analyzed plasma diluted 2-, 3-, 5-, 10 Figure 2A : HDL, LDL, and VLDL peaks are well resolved. A shoulder peak from Lp(a) was also observed in some samples. In the example shown in Figure 2A , the time for the HDL, LDL, and VLDL peaks to reach their maimn was 40, 110, and 180 a, respectively, from the beginning of the HDL peak.
Cholesterol in five lipoprotein classes [HDL, Lp(a), LDL, IDL, and VLDL] was quantified by decomposing this corresponds to an upper limit of 1800 mg/L for cholesterol in each lipoprotein class. Linear least-square characteristics of the calibration curves for HDL-C, Lp(a)-C, L1)L-C, and VLDL-C are also described in Figure 3 . Slopes (area units per mg/L concentration) of all curves were very similar, indicating similar reaction kinetics for each lipoprotein class. As discussed later, the reaction is not carried to completion in this system. To study the reproducibility of analysis, we analyzed aliquots of the same plasma (diluted 30-fold) in five rotors (seven aliquots per rotor plus an aliquot of a calibration plasma with known cholesterolconcentration to calibrate the total area under the proffle curve in terms of cholesterol concentration). Reproducibility (CV) of TC determinations by VAP-JIfs for aliquots within a rotor ranged from 1.35% to 3.15%; among all aliquots from five rotors, the CV was 2.45% (Table 1) . The cholesterol content of individual lipoprotein class was quantified after decomposing the cholesterol profile; the reproducibility of the quantification of lipoprotein classesby this system is also indicatedin Table 1 . The CV values for VLDL-C were somewhat higher than for the other lipoprotein classes,becauseof the low VLDL-C concentration (90 mgfL) in the plasma sample used in this experiment.
Comparison of VAP-H/
with NWLRL method. We analyzed venous samples from 23 fasting subjects,using both the VAP-llfs method and the NWLRL Beta Quantification method. TC values obtained from VAP-Jlfs and from the NWLRL method agreed very well ( Table  2 ). The VAP method separates Lp(a)-C and IDL-C from true LDL-C; thus, to be consistent with the usual reported values for L1)L-C, as described by the National Cholesterol Education Program (NCEP; 15) and measured by the Beta Quantification method, we summed the results for Lp(a)-C, LDL-C, and IDL-C measured by the VAP-Hfs method and henceforth referred to this value as LDL-C(NCEP). Comparisons of HDL-C, LDL-C(NCEP), and VLDL-C are summarized in Table 2 .
Results of the VAP-Ufs method for cholesterol concentrations in these lipoproteins were highly correlated with those of the NWLRL method. Assessments of the methods by comparing paired differences showed that HDL-C values were consistently lower (-8.6%) for the VAP-llfs method than for the NWLRL method (mean ± SE paired difference = -43.5 ± 4.6 mg/L; P <0.001), and that LDL-C(NCEP) values were consistently higher (7.2%) for the VAP-llfs method than for the NWLRL method (mean paired difference 79.3 ± 11.2 mgIL; P <0.001). VLDL-C values were also lower (-11.8%) for the VAP-Ufs method than for the NWLRL method (mean paired difference = -22.0 ± 6.1 mg/L;P <0.002), but this decrease was not consistent for all samples. Paired differences for TC between the methods were not significant (mean paired difference = 3.5 ± 11.1 mgIL).
Evaluation
of fingerstick blood sampling. Table 3 also show good correlation between fingerstick and venous cholesterol values in these lipoprotein classes.
Cholesterol proffle analysis of fingerstick plasma by the VAP-llfs method was also compared with profiles of venous blood analyzed by the NWLRL Beta Quantification method (Table 4) . Results were highly correlated between the two methods. Once again, paired comparisonsshowed that HDL-C values were consistently lower (-7.6%) for the VAP-llfs method (mean paired difference = -38.3 ± 6.9mg/L;P <0.001), and LDL-C(NCEP) values were consistently higher (5.1%) (mean paired difference = 56.3 ± 11.7 mg/L; P <0.001). The mean paired difference (-17.9 ± 7.2 mg/L) for VLDL-C was less significant (P <0.05). PC differences were not significant (mean paired difference = 5.7 ± 10.6 mg/L).
Discussion
Both research and clinical medicine require analysis for cholesterol in lipoprotein classes, in addition to analysis for PC concentrations. The VAP-llfs method directly analyzes all lipoprotein classes,in contrast with methods used in most clinical laboratories. The most common methods for determining the cholesterol profile involve multiple analyses with several aliquota of the same sample. Therefore, the accuracy of the det.ermination strongly depends on the accuracy of the individual analyses. For instance, the Friedewald equation (LDL-C = PC -HDL-C -TG/5, where PG = triglycerides) involves not only multiple analyses, but multiple assumptions as well (8): i.e., that the precipitation separation of ape B-containing lipoproteins from HDL is complete, and that VLDL-C is accurately estimated by the factor PG/S. The Beta Quantification method is better in that VLDL-C is measured directly, but this requires an additional analytical step. The method de- b.c As In Table 2 . veloped previously in our laboratory (VAP-I) largely overcomes these problems. It is rapid-eight samples including a calibration plasma sample can be analyzed in -45 mm, excluding centrifugation time-and can determine the cholesterol concentrations in all lipoprothin classes in a single aliquot of sample in a single analysis. However, the VAP-I method, which uses an air-segmented continuous-flow system (Technicon AutoAnalyzer)
#{176}LDL-C(NCEP).
to assay cholesterol, requires 1.3 mL of plasma and is thus unsuitable for analyzing fingerstick or other low-volume samples. In contrast, the present system, VAP-llfs, based on a nonsegmented continuousflow system with a narrow-bore Teflon coil reactor, requires only 18 pL of plasma.
In VAP-llfs, the sample is continuously mixed with a nonsegmented stream of cholesterol reagent in a flow module containing a Y-shaped capillary channel. Dispersion, which causes overlapping of the lipoprotein peaks in other systems, is controlled by minimizing convection and diffusion of the sample. To do this, we adjusted the flow rates and reduced the length and bore size of the tubing, thereby minimizing the total volume of the tubing. At any given time, the total volume of reagent and sample in the coil is only 0.75 mL. Dispersion is also minimized by placing downstream from the detector the peristaltic pump used to draw the reaction mixture into the Teflon coil; the larger diameter of the pump tubing and the pump rollers could increase the dispersion if the sample were to pass through the pump before passing through the detector.
Because the sample inside the VAP-llfs flow system is less diluted than in the VAP-I, in which the sample is (Table 2) . Moreover, reproducibility ( Table 1) lipoprotein fractions were statistically significant between the two methods, the results of both methods correlated very well. The differences in HDL-C and Ll)L-C(NCEP) between the two methods were consistent, the HDL-C values being lower and the LDL-CXNCEP) values higher by the yAPIIfs method. However, the negative differences observed for venous (-8.6%, Table 2 ) and fingerstick (-7.6%, Table 4 ) HDL-C values were within the mmnmujn bias of ±10% required by the CDC-NHLBI Lipid Standardization Program (22) . Although widely used to isolate HDL becauseof their simplicity, the accuracy and precision of the precipitation methods depend strongly on complete removal of apo-B-containing lipoproteins. Accurate adjustments of pH, reagent concentration, ionic strength, and temperature are critical to the complete removal of apo-B-oonf.ining lipoproteins. Traces of LDL or VLDL remnining in the supernate can lead to overestimation of HDL-C (23) . Significant constant differences among various precipitation methods (24, 25) and between precipitation methods and other methods of HDL-C determination have been reported (25,26). The constant differences in H])L-C values observed between the present two methods are due to the use of two methodologies (i.e., precipitation and ultracentrifugation) that separate HDL by different mechanisms, the former based on formation of a complex with apo-B-cont.aining lipoproteins and the latter based on differences in hydrated densities of lipoproteins.
The CDC-NHLBI Lipid Standardization Program has not yet established Reference Methods for measuring LDL-C(NCEP) or VLDL-C. Even though the Beta Quantification method is generally accepted as the method of choice for LDL-CXNCEP) measurement, its accuracy strongly dependson the accuracy ofthe HDL-C determination. In the Beta Quantification method, LDL-C(N-CEP) is calculated by subtracting the HDL-C value from the cholesterol value measured in the infranate after plasma ultracentrifugation.
Therefore, any positive error in HDL-C determination by the Beta Quantification method will result in a negative error for LDL-C(NCEP) values. Thus, systematic positive differences in LDL-C(NCEP) values of the VAP-llhs method with the Beta Quantification values (7.2% for venous, Table 2 ; and 5.1% for fingerstick, Table 4 ) are due largely to the corresponding negative differences in Hl)L-C values between the two methods. Measuring LDL-C(NCEP) by the Beta Quantification method is time consuming and labor intensive compared with the VAP-IJfs method, and is also an indirect procedure. The need for a reliable and direct method for measuring LDL-C(NCEP) suitable for routine use in the clinical laboratory has been emphasized (27) . Although the percentage differences in VLDL-C between the two methods were somewhat high (-11.8% for venous, Table 2 ; and -9.1% for fingerstick, Table 4), the absolute differences in the mean values were small (22 mg/L for venous blood, 17 mgfL for fingerstick blood). These higher percentage differences in VLDL-C are probably attributable to the high CVs for this analyte in the VAP-flfs method and the relatively small concentrations of VLDL-C in this set of subjects. CVs as great as 14% for VLDL-C were reported in a similar comparison study (28) .
In summary, this highly sensitive new method (yAPUfs) simultaneously measures cholesterol in all lipoprotein classes in only 18 p.L of plasma. The method can be adapted for assaying lipoproteincholesterolin fingerstick blood. The VAP-ilfa method is reliable, as indicated by reproducibility ( (compared with yAP-I) are all significant advantages of the VAP-llfs method. The continuous proffle provided by VAP-llfs allows more precise determination of the nature of lipid abnormalities than can conventional methods and allows direct comparisons of two profiles.
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